Meeting
2024 ASCO Gastrointestinal Cancers Symposium
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA).
Authors
Christopher Hanyoung Lieu
University of Colorado Cancer Center, Aurora, CO
Christopher Hanyoung Lieu , Guan Yu , Scott Kopetz , Shannon L. Puhalla , Peter C. Lucas , Ibrahim Halil Sahin , Dustin A. Deming , Philip A. Philip , Theodore S. Hong , Yesenia Rojas-Khalil , Jonathan M. Loree , Norman Wolmark , Greg Yothers , Thomas J. George , Arvind Dasari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Other
Clinical Trial Registration Number
NCT05174169
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr TPS243)
DOI
10.1200/JCO.2024.42.3_suppl.TPS243
Abstract #
TPS243
Poster Bd #
P11
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).
First Author: Christopher Hanyoung Lieu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).
First Author: Arvind Dasari
Poster
2022 ASCO Annual Meeting
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.
First Author: Arvind Dasari
Poster
2024 ASCO Breakthrough
CORRECT-MRD I: A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD).
First Author: Yuichiro Tsukada